Prevnar is Model for Blockbuster Vaccines

Prevnar is Model for Blockbuster Vaccines

NEW YORK (GBI Research), 21 March 2013

Developing new vaccine products is a costly, lengthy and uncertain process, but the resounding success of the first blockbuster vaccine is making healthcare companies sit up and take notice of this potential goldmine, according to a new report by GBI Research.

The new report* states that the vaccines market, which was once considered by pharma giants as a low-profit segment, is showing a turnaround after the resounding success of Prevnar 13. This vaccine was approved by the FDA in December 2011 for people aged 50 and older to prevent pneumonia and invasive disease caused by the bacterium Streptococcus pneumoniae (S. pneumoniae). Prevnar 13 was already approved for use in children aged six weeks to five years old, for the prevention of invasive disease and otitis media caused by the bacterium S. pneumoniae.

Although the pediatric vaccines segment has historically always been larger than the adult vaccines segment, the global vaccines market has seen a paradigm shift in recent years, and the industry is becoming more reliant on the adult vaccine segment. This shift has primarily been due to an increase in awareness about the benefits of adult vaccination, especially within the elderly and vulnerable population. FDA recommends one dose of pneumococcal vaccine for people aged 65 years and above to prevent pneumonia.

Vaccines can generate high revenues, being priced at a premium, and offer an attractive challenge to existing market players and pharma giants alike. Prevnar's market success means that the pneumococcal vaccines segment for adults and adolescents is growing at a rapid pace, and is expected to reach a value of US$1.7 billion by 2018 from only US$515m in 2011. This market segment is expected to be dominated by Prevnar, leaving a marginal share for competitors. However, the strong global pipeline of adult and adolescent vaccines boasts a 52% share of vaccine candidates in the Phase III stage of clinical development, suggesting that several new products will be made available in the coming years.

GBI Research values the adult and adolescent vaccines market in the US, the UK, France, Germany, Italy, Spain, and Japan in 2011 at US$7.2 billion, and expects growth at a Compound Annual Growth Rate (CAGR) of 5.6%, to reach a value of US$10.5 billion in 2018.

*Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth

-ENDS-

-NOTES TO EDITOR-

This report provides insights into the vaccines in the adult and adolescent vaccines market in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. This includes market forecasts up to 2018, in-depth analysis of the vaccines for the adult and adolescent market, and insights into the adult and adolescent vaccines market's Research and Development (R&D) pipeline. It also provides in-depth analysis of the unmet needs, drivers and barriers that affect the global adult and adolescent vaccines market.

 This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

-ABOUT GBI RESEARCH-

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at [email protected].

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.